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Background: More accurate risk assessments are needed to improve prostate
cancer management.
Objective: To identify blood-based protein biomarkers that provided prognostic
information for risk stratification.
Design, setting, and participants: Mass spectrometry was used to identify bio-
marker candidates from blood, and validation studies were performed in four
independent cohorts retrospectively collected between 1988 and 2015.
Outcome measurements and statistical analysis: The primary outcome objectives
were progression-free survival, prostate cancer–specific survival (PCSS), and over-
all survival. Statistical analyses to assess survival and model performance were
performed.
Results and limitation: Serum leucine-rich a-2-glycoprotein 1 (LRG1) was found to
be elevated in fatal prostate cancer. LRG1 provided prognostic information indepen-nd
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first 3 yr. A high LRG1 level is associated with an average of two-fold higher risk of
disease-progression and mortality in both high-risk and metastatic patients.
However, our study design, with a retrospective analysis of samples spanning
several decades back, limits the assessment of the clinical utility of LRG1 in today’s
clinical practice. Thus, independent prospective studies are needed to establish
LRG1 as a clinically useful biomarker for patient management.
Conclusions: High blood levels of LRG1 are unfavourable in newly diagnosed
high-risk and metastatic prostate cancer, and LRG1 increased the accuracy of
risk stratification of prostate cancer patients.
Patient summary: High blood levels of leucine-rich a-2-glycoprotein 1 are
unfavourable in newly diagnosed high-risk and metastatic prostate cancer.
© 2020 The Author(s). Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Nearly 1.3 million men were estimated to be diagnosed with
prostate cancer (PCa) worldwide in 2018 [1]. Several risk
assessment tools are in clinical use to guide treatment and
communicate prognostic information [2]. However, as these
tools are primarily developed for the prediction of
biochemical recurrence, a large diversity has been reported
in the accuracy of predicting long-term outcomes [3]. Hence,
some guidelines, including those of the National Compre-
hensive Cancer Network (NCCN), are now endorsing
biomarker guidance upon treatment decisions to enable
better precision [4,5].
The multifocal nature and the intra- and interheter-
ogeneity of PCa [6,7] represent a challenge for tissue-based
biomarker discovery. Biological fluids, on the contrary, are
easily collected, allow for repeated sampling, and can
function as an unbiased source of biomarkers to mirror the
complexity of PCa. Unfortunately, the collection of biologi-
cal samples has been an underfunded effort in many
institutional environments; thus, paraffin-embedded pros-
tate specimens have been the primary source of cancer
biomarker research so far, which is also reflected in the
types of tests approved [8]. Although valuable information
can be conveyed from tissue-based tests, these are
vulnerable for sampling biases, and consequently utility
has been most promising in a postprostatectomy setting [4].
In recent years, the focus of biomarker research in PCa has
been on reducing overdiagnosis due to low specificity of the
prostate-specific antigen (PSA) test. Several promising blood-
based biomarkers and models have been proposed, spanning
multiple kallikreins and their isoforms (4KScore [9], Prostate
Health Index [10]), and panels of single nucleotide polymor-
phisms and proteins (STHLM3 [11]), to circulating tumour
DNA [12]. However, to date, only the 4KScore has been tested
for its utility in predicting long-term outcomes, such as
metastasis-free and disease-specific survival [13,14], and at
present, no noninvasive biomarkers have been reported to
improve on current standard risk nomograms as predictors of
treatment response.
In this study, we sought to identify blood-based proteins
that would enable higher precision in predicting unfavour-able PCa and long-term outcomes upon diagnosis. We have
identified and validated a blood-based protein, leucine-rich
a-2-glycoprotein 1 (LRG1), which associates with meta-
static PCa and provides increased accuracy in predicting
survival outcomes.
2. Patients and methods
2.1. Study design
This study was planned in agreement with the reporting recommenda-
tions for tumour marker prognostic studies (REMARK) guidelines, as
outlined in the Supplementary material (REMARK), and a summary of
the study is illustrated in Supplementary Fig. 1.
2.2. Patient samples and ethical approvals
Baseline characteristics for the cohorts used are shown in Table 1, and
cohorts are further described in the Supplementary material (Materials
and methods). In brief, samples from four independent patient cohorts
were identified. A discovery cohort (JANUS I, n = 61) was built from the
prospective collected Janus Serum Bank (Norway) using a case-control
design for PCa and no cancer (control). Samples were included based on
cancer diagnosis at blood draw or no cancer diagnosed within 10 yr. A
confirmation cohort was generated drawing samples from the prospec-
tively collected Cancer of the Prostate Sweden (CAPS) with a case-control
design to represent no PCa (n = 50), before PCa (n = 50), indolent PCa
(n = 50), and fatal PCa (n = 50). The inclusion criterion was a minimum of
10 yr of follow-up (FU). Next, an explorative cohort (JANUS II, n = 82) was
built to assess LRG1 levels in different NCCN risk strata and confirm
association with survival. A final validation cohort (ProMPT-OUH,
n = 451) was created by combining 385 samples from the ProMPT
(Prostate Cancer Mechanisms of Progression and Treatment) study with
66 samples from a local study at the Oslo University Hospital (OUH).
All patients received best of care by their treating physician, and the
treatment distribution of patients in all cohorts is described in Table 1.
This study was approved by relevant ethical committees in each
country, as detailed in the Supplementary material (Materials and
methods). Written informed consent was obtained from all participants.
2.3. Laboratory methods
All sample handling was performed in a blinded fashion and according to






Fig. 1 – LRG1 is elevated in blood from PCa patients and associates with fatal PCa. Tukey boxplots demonstrating the concentration of LRG1 in blood
from donors grouped by PCs diagnosis at the time of sampling in (A) JANUS I and (B) CAPS cohorts. The p values were established by MWU test
comparing the difference between groups.
CAPS = Cancer of the Prostate Sweden; LRG1 = leucine-rich a-2-glycoprotein 1; MWU = Mann-Whitney U test; ns = not significant; PCa = prostate cancer.
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be reviewed in the Supplementary material (Materials and methods).
2.3.1. Mass spectrometry
Abundant proteins in full serum were depleted using ProteoSpin
Abundant Serum Depletion Kit (Cat. #17300; Norgen Biotek, Thorold,
Ontario, Canada) according to the protocol provided by the manufactur-
er.
Depleted serum proteins (2.5 mg) were used for in-solution trypsin
digest, and peptides were analysed by an ESI-Orbitrap (LTQ Orbitrap XL;
Thermo Scientific, Bremen, Germany) mass spectrometer coupled to a
nano-LC system and label-free quantification was performed. The
samples were analysed once.
2.3.2. Immunoassay
The levels of LRG1 in serum/plasma samples were measured in
duplicates using a commercially available solid-phase sandwich
enzyme-linked immunosorbent assay (ELISA) kit (Cat.no JP27769; IBL
International GmbH, Hamburg, Germany) according to the manufac-
turer’s description.
2.4. Statistical analysis
A detailed description of the statistical analysis is provided in the
Supplementary material (Material and methods). Two-sided p <
0.05 was considered significant. In brief, Fisher exact test and
standardised mean difference (SMD) were used to assess significant
differences in quantified peptide spectra from cancer samples compared
with control samples. Two-sided Mann-Whitney U test (MWU) and SMD
were used to measure differences in concentrations of LRG1 in grouped
samples. Kaplan-Meier estimates and Cox proportional hazard model,
supplemented with log-rank test and Harrell’s concordance index (c-
index), respectively, was used to assess time-to-event outcomes:
progression-free survival (PFS), PCa-specific survival (PCSS), and overall
survival (OS). Cut-point for LRG1 dichotomisation was established
through grouping LRG1 concentrations into tertiles in JANUS II, where
the tertile cut-point that significantly enriched for mortality (compared
with the first tertile) by log-rank test was chosen. Time-dependent
receiver operator characteristic curve and decision curve analysis were
performed to assess added value for predicting survival outcomes for
patients.2.5. Statistical power calculations
Sample size needed to perform a validation study was calculated
assuming two-sided equality using a Cox PH model [15] and with a
conservatively modified hazard ratio (HR) estimate from the third tertile
in the JANUS II cohort. Assuming a 10% incidence of PCa-specific
mortality at 10 yr after diagnosis and allowing a 5% type I error rate, at
least 414 samples were needed to detect an HR of 3.0 with 90% power.
3. Results
3.1. LRG1 is elevated in blood and associates with aggressive
PCa
A mass spectrometry (MS) analysis of 21 serum samples
from the Janus Serum Bank identified peptide spectra from
a total of 93 proteins (Supplementary Table 1). Of the
21 serum samples analysed, 10 donors harboured PCa at
time of blood draw, whereas 11 did not get a PCa diagnosis
within 10 yr of FU (median 14.9 yr [interquartile range or
IQR 11.0–17.2]). Six proteins showed a significant upregula-
tion in the cancer group (alpha-1-acid glycoprotein
2 [ORM2], complement C4-A [C4A], desmoplakin [DSP],
serum amyloid A protein [SAA1], junction plakoglubulin
[JUP], and LRG1). LRG1 showed that the greatest fold change
(6.9; Fisher exact test with Benjamini-Hochberg multiple-
testing correction: p = 0.028) in detected peptides compar-
ing normal and PCa samples (Supplementary Table 1),
ranked significant by SMDs (0.88; MWU p = 0.042), was
through literature also implicated in aggressive PCa [16,17]
and was therefore selected for further exploration. The
finding was confirmed by ELISA using serum from
61 samples from the JANUS I cohort (of which 21 was
previously used in MS analysis). Serum LRG1 levels were
significantly higher in PCa than in healthy control samples
(SMD: 0.79, MWU p < 0.001; Fig. 1A). In the CAPS cohort,
LRG1 concentrations were raised notably in men with PCa
(MWU p < 0.001) compared with controls, and further
Table 1 – Baseline characteristics of patient cohorts
JANUS I CAPS JANUS II ProMPT-OUH
Pre-PC PC No PC Pre-PC Indolent PC Fatal PC PC PC
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Total 31 (100) 30 (100) 50 (100) 50 (100) 50 (100) 50 (100) 82 (100) 430 (100)
Year of sample collection 1972–2003 1988–2009 2002–2003 2002–2003 2001–2004 2001–2004 1990–2011 1995–2015
Follow-up time (yr), median (IQR) 17.3 (12.5–22.8) 1.59 (0.9–3.6) 9.0 (8.6–9.6) 9.2 (8.7–9.7) 8.6 (7.4–10.0) 0.44 (0.25–0.63) 6.8 (2.7–7.7) 6.8 (5.4–8.8)
Time from sampling to diagnosis (yr),
median (IQR)
14.9 (11.0–17.2) –0.4 (–1.4 to 0.0) – – 4.2 (3.0–5.4) –0.4 (–0.5 to –0.3) –0.4 (–0.6 to –0.3) –0.3 (–0.8 to –0.2) 0.3 (0.1–0.5)
Age at sampling (yr), median (IQR) 43 (41–51) 60 (57–64) 65 (61–73) 67 (62–72) 76 (74–78) 66 (60–73) 61 (59–67) 65 (60–69)
PSA (ng/mL), median (IQR) NA 7.0 (4.0–8.9) 165.5 (45.0–511.0) 10.1 (6.4–37.6) 8.6 (5.6–15.1)
PSA at diagnosis (ng/mL)
<10 NA 50 (100) 0 (0.0) 38 (46.3) 243 (56.5)
10–20 NA 0 (0.0) 0 (0.0) 13 (15.9) 109 (24.2)
>20 NA 0 (0.0) 50 (100) 25 (30.5) 78 (18.2)
Missing 30 (100) 0 (0.0) 0 (0.0) 6 (7.3) 0 (0.0)
Gleason score
6 NA 50 (100) 1 (2.0) 30 (36.6) 107 (24.9)
7 NA 0 (0.00) 11 (22.0) 19 (23.3) 204 (47.4)
8–10 NA 0 (0.00) 35 (70.0) 23 (28.0) 109 (25.3)
Missing 30 (100) 0 (0.00) 3 (6.0) 10 (12.2) 10 (2.3)
T stage
T1 4 (13.3) 30 (60.0) 2 (4.0) 24 (29.3) 47 (10.9)
T2 3 (10.0) 20 (40.0) 6 (12.0) 33 (40.2) 145 (33.7)
T3 12 (40.0) 0 (0.00) 26 (52.0) 15 (18.3) 202 (47.0)
T4 1 (3.3) 0 (0.00) 13 (26.0) 6 (7.3) 9 (2.1)
Missing 10 (33.3) 0 (0.00) 3 (6.0) 4 (4.9) 27 (6.3)
Metastasis
Not known (N0/Nx and M0/Mx) 3 (10.0) 50 (100) 13 (26.0) 55 (67.9) 360 (83.7)
Lymph node (N1+ and M0/Mx) 9 (30.0) 0 (0.0) 2 (4.0) 0 (0.0) 18 (4.2)
Distant (N0/Nx and M1+) 17 (56.7) 0 (0.0) 32 (64.0) 25 (30.9) 24 (5.6)
Lymph node and distant (N1+ and M1+) 1 (3.3) 0 (0.0) 3 (6.0) 1 (1.2) 28 (6.5)
NCCN risk group
Low NA 28 (56.0) 0 (0.0) 8 (9.9) 56 (13.0)
Intermediate NA 22 (44.0) 0 (0.0) 30 (37.0) 87 (20.2)
High NA 0 (0.0) 13 (36.0) 17 (20.7) 217 (50.5)
Metastasis 20 (66.7) 0 (0.0) 37 (74.0) 27 (32.9) 70 (16.3)
Unknown 10 (33.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Primary treatment
Radical prostatectomy 0 (0.0) 0 (0.0) 0 (0.0) 35 (43.2) 183 (42.6)
Radiation with or without hormone therapy 0 (0.0) 3 (6.0) 0 (0.0) 32 (39.5) 210 (48.8)
Hormone therapy 0 (0.0) 9 (18.0) 48 (96.0) 10 (12.3) 36 (8.4)
Unknown/not recorded 30 (100) 38 (76.0) 2 (4.0) 4 (4.9) 1 (0.2)
Overall mortality
Censored 7 (22.6) 6 (20.0) 41 (82.0) 44 (88.0) 31 (62.0) 0 (0.00) 51 (63.0) 359 (83.5)
Event 24 (77.4) 24 (80.0) 9 (18.0) 6 (12.0) 19 (18) 50 (100) 30 (37.0) 71 (16.5)
Cause of death
Prostate cancer 22 (100) 21 (100) 0 (0.0) 1 (100) 0 (0.0) 50 (100) 25 (83.3) 26 (36.7)
Other cause 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 5 (16.7) 7 (9.6)
Unknown/Not recorded 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 38 (53.5)
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< 0.0001; Fig. 1B and Supplementary Table 2). No difference
was observed between healthy controls and men who were
diagnosed with PCa within 5 yr following blood draw.
3.2. LRG1 is independent of metastasis in predicting fatal PCa
A marked elevation of LRG1 concentrations was further
observed in patients with metastatic PCa and fatal PCa in a
new sample set of 82 patients from the Janus Serum Bank
(JANUS II; Fig. 2A and Supplementary Table 3). The new
sample set included 25 (30.9%) samples from men who
had died from PCa (median FU 1.3 yr [IQR 0.8–3.3]). The
samples were grouped by tertiles of LRG1 concentrations
(first <26 mg/mL, second 26–37 mg/ml, and third 38 mg/
mL). Using the first tertile as a reference (median FU 7.5 yr
[IQR 6.4–7.9]), a Kaplan-Meier analysis showed signifi-
cantly shorter survival in patients with LRG1 levels in the
third tertile (median 2.5 yr [IQR 0.7–7.3]), whereas
patients with LRG1 levels in the second tertile did not
demonstrate a significant difference in PCSS (median
6.4 yr [IQR 3.0–7.3]; Fig. 2B). Consequently, the third
tertile was chosen for further dichotomisation of LRG1
into high (third tertile) and low levels (first and second
tertiles).
In a multivariable Cox proportional hazard model, both
continuous and dichotomised LRG1 showed independence
of metastasis in predicting PCa-specific mortality (HR = 1.02,
[95% confidence interval {CI} 1.01–1.03], p = 0.001 and HR =
1.88 [95% CI 1.05–3.35], p = 0.033). A time-dependent ROC
analysis showed that the gained accuracy of adding LRG1 to
metastatic status was most apparent in the first 3 yr of FU
(Fig. 2C). Decision curve analyses show that adding LRG1 to
the model provides not only increased sensitivity and
specificity, but also an additional clinical benefit in a 3-yr
perspective (Fig. 2D).
3.3. LRG1 provides increased precision in established risk
stratification
To further confirm that LRG1 is an independent prognostic
biomarker, we analysed samples from the ProMPT-OUHTable 2 – Univariable and multivariable Cox proportional hazard mode
Univariable Multivariable model excludin
LRG1
HR 95% CI p value HR 95% CI p val
LRG1 (cont.) 1.02 (1.01–1.02) <0.0001 – – – 
LRG1 (dicho.) 2.08 (1.47–2.94) <0.0001 – – – 
PSA (cont., ng/mL) 1.00 (1.00 –1.00) <0.0001 1.00 (1.00 –1.00) 0.53
GS 6/7 vs GS 8 3.09 (2.16–4.42) <0.0001 1.54 (1.16–2.03) 0.00
T1/2 vs T 3 1.74 (1.19–2.55) 0.004 1.06 (0.80–1.39) 0.68
Metastasis 7.03 (4.96–9.95) <0.0001 3.39 (2.59–4.43) <0.00
C-index 0.708 (0.657–0.759) 
p value Ref. 
CI = confidence interval; cont. = continuous; dicho. = dichotomised; GS = Gle
PSA = prostate-specific antigen; Ref. = reference.cohort using the cut-off established in the JANUS II cohort
(>38 mg/mL). The ProMPT-OUH cohort included data on
progression and overall mortality, whereas confirmed cause
of death was available only for 33 (46.3%). The association of
LRG1 with PFS and OS in all risk strata and in metastatic
patients is presented as Kaplan-Meier plots (Fig. 3A–D and
Supplementary Fig. 2). Very few deaths/events occurred in
the low- and intermediate-risk strata (Supplementary
Fig. 2). A high LRG1 level was associated with a higher
probability of both disease progression and mortality than
low LRG1 levels in the NCCN high-risk strata (Fig. 3A and 3C)
and among patients with metastatic disease (Fig. 3B and
3D).
3.4. LRG1 enhances the subclassification of high-risk patients
Sufficient clinical information was available for 200 NCCN
high-risk patients in the ProMPT-OUH cohort to subclassify
patients according to the Cambridge Prognostic Group
(CPG) [18]. This model splits typical NCCN high-risk patients
into two distinct groups, CPG4 and CPG5. Addition of
information on LRG1 levels on top of this model demon-
strated a further subclassification of high-risk patients for
progression and mortality (Fig. 4).
Overall, in a multivariable Cox proportional hazard
model with PSA, Gleason score, T stage, and metastasis,
LRG1 demonstrated an independent association with PFS
and a significant improvement in accuracy both as a
continuous or as a dichotomised measure (Table 2).
Comparing c-indices over time, these improvements were
most prominent within the first years (Supplementary
Fig. 3A and 3B).
4. Discussion
In this study, we identified LRG1 as a marker of fatal PCa.
This is the first study to report and validate the independent
prognostic capacity and clinical significance of elevated
LRG1 in PCa. We establish the clinical impact of elevated
LRG1 through validation in a number of independent
patient cohorts, and subsequent incorporation of LRG1 into
established and novel risk stratification tools.lling for progression-free survival in the ProMPT-OUH cohort
g Multivariable model with LRG1
cont.
Multivariable model with LRG1
dicho.
ue HR 95% CI p value HR 95% CI p value
1.01 (1.00–1.01) 0.019 – – –
– – – 1.60 (1.25–2.05) <0.0001
 1.00 (1.00–1.00) 0.39 1.00 (1.00–1.00) 0.43
3 1.48 (1.11–1.96) 0.007 1.11 (0.84–1.46) 0.013
 1.08 (0.82–1.43) 0.56 1.23 (0.95–1.58) 0.12
01 3.18 (2.39–4.18) <0.0001 3.42 (2.559–4.50) <0.0001
0.744 (0.697–0.791) 0.737 (0.690–0.784)
0.008 0.031






Fig. 2 – LRG1 was an independent prognostic factor in the JANUS II cohort. (A) Tukey boxplot illustrating serum distribution of LRG1 grouped
according to the NCCN risk criteria. Filled and open circles illustrate the PCa-specific mortality status at the last FU (median 6.8 yr, [IQR 2.5–7.7]).
Significant differences were assessed by MWU testing. (B) Kaplan-Meier survival analysis and log-rank testing of prostate cancer–specific survival
(PCSS) of patients grouped by LRG1 concentrations (tertiles: <26 mg/mL [first/low], 26–37 mg/mL [second/inter], and 38 mg/mL [third/high]). (C) Time-
dependent c-index for PCSS. Metastasis (blue) was included as a covariate in the clinical model and supplemented with PSA (blue, dashed) or LRG1
(orange). (D) Time-dependent decision curve analyses of combining LRG1 and metastasis for predicting PCSS within the first 3 yr after diagnosis.
AUC = area under the curve; CI = confidence interval; HR = hazard ratio; cont. = continuous; IQR = interquartile range; LRG1 = leucine-rich a-2-
glycoprotein 1; Met = metastasis; MWU = Mann-Whitney U test; NCCN = National Comprehensive Cancer Network; PCa = prostate cancer; PSA = prostate-
specific antigen; Ref. = reference.
E U R O P E A N U R O L O G Y O P E N S C I E N C E 2 1 ( 2 0 2 0 ) 5 1 – 6 056A particular added value to current clinical risk factors
was observed in predicting early mortality (PCSS < 3 yr) in
JANUS II and further confirmed in the ProMPT-OUH cohort,
where similar survival proportions were observed in high-
risk patients with high LRG1 levels and patients with
metastasis and low LRG1 at 2-yr FU.Recently, a head-to-head comparison of widely used risk
stratification tools was reported [5]. The novel CPG risk
group system outperformed other risk grouping systems,
and our data demonstrate further improvement when
adding LRG1 into the model. This is particularly true for
predicting early progression and/or mortality.
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Fig. 3 – LRG1 provides enhanced precision for predicting progression and mortality to established risk stratification. Kaplan-Meier plot and log-rank
test for progression and overall survival in the ProMPT-OUH cohort grouped according to the NCCN risk strata, (A and C) high risk and (B and D)
metastasis, which were supplemented with dichotomised LRG1 levels (high/low).
HR = hazard ratio; LRG1 = leucine-rich a-2-glycoprotein 1; NCCN = National Comprehensive Cancer Network; OS = overall survival; PFS = progression-free
survival; Ref. = reference.
E U R O P E A N U R O L O G Y O P E N S C I E N C E 2 1 ( 2 0 2 0 ) 5 1 – 6 0 57LRG1 has previously been implicated as a promising
biomarker for aggressive PCa using a PTEN knockout mouse
model [16]. Later, Rehman et al [17] performed proteomic
studies directly on serum samples from patients with
benign hyperplasia, and localised and metastatic disease,
and found LRG1 to be elevated in more aggressive PCa. LRG1
was recently incorporated into a proteomic signature for the
detection of aggressive PCa [19] and has been found to be
elevated in PCa patients with bone metastasis [20].Numerous reports have associated LRG1 with unfavour-
able outcomes in multiple cancer types [21–24], suggesting
a conserved pan-cancer role for LRG1 in disease progres-
sion. Hence, a thorough understanding of the biological role
of LRG1 may both improve its clinical utility and also help
identify potential actionable targets. The function of LRG1 is
so far largely unknown, although publications have shown
that LRG1, through TGFb signalling, regulates angiogenesis,
migration, and invasion [25–30]. Furthermore, both
0 2 4 6 8 10
Time to even t (yr)
90 90 88 71 31
46 42 32 19
39 37 30 17









0 2 4 6 8 10

















LRG1 low 90 88 80 57 18 15
47 45 33 17 7 6
39 36 35 27 15 13






































HR 3.76 (1.67-8.47), p = 0.001
HR 2.29 (1.09-4.81), p = 0.029
HR 1.18 (0.49-2.81), p = 0.72
Ref.
HR 9.9 5 (2.57-38.6), p < 0.001
HR 1.8 2 (0.37-9.01), p = 0.47
HR 4.0 4 (1.01-16.2), p = 0.049
Ref.
No. at risk No. at risk
47
39
Fig. 4 – LRG1 enhances the subclassification of high-risk patients. Kaplan-Meier plot and log-rank test for progression and overall survival in high-risk
patients in the ProMPT-OUH cohort subclassified according to the Cambridge Prognostic Group (CPG4 and CPG5), which were supplemented with
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interaction with cytochrome C have been reported
[25,26,28–35]. LRG1 is a key regulator of myeloid differen-
tiation [36,37], expressed in most myeloid linages [38], and
induced in response to specific acute-phase cytokines
[29,39], with associations to autoimmune diseases such
as rheumatoid arthritis, Crohn’s disease, and ulcerative
cholitis [40–43]. This implicates a significant biological role
of LRG1 in inflammation, but also several important
hallmarks of cancer development and progression, which
might shed light on the highly diverse outcomes among
patients diagnosed with high-risk and metastatic PCa.
Potentially, this could provide guidance towards adjuvant
therapies, treatment selection, and enrolment into clinical
trials for a significant patient group.
However, our study has been limited in its design to
assess the true relevance of LRG1 in PCa and disease
progression. Several questions arise such as whether blood
levels of LRG1 is primarily a contribution from the tumour,
its microenvironment, or a systemic effect to a disseminated
cancer, and whether LRG1 can be affected by cancer
treatment and can be used to monitor treatment effect.
Information on PTEN status in tumour tissue, immune cell
infiltration, or activity would have brought important
information regarding LRG1’s relevance in a clinical setting.
Furthermore, an assessment of the association and impli-
cation of elevated LRG1 blood levels in PCa patients with
autoimmune diseases will need to be further performed
prior to implementing LRG1 into risk stratification tools.
The long FU times of the cohorts included in this study
limit the assessment of clinical usefulness of LRG1 in today’s
clinical practice. These cohorts were collected before
multiparametric magnetic resonance (mpMR) imaging–guided biopsies became an option in clinical practice.
mpMR imaging has high accuracy for detecting clinically
significant disease, implying that fewer men are diagnosed
with low-grade disease nowadays [44,45]. However, iden-
tification of ways towards prioritising men upfront for
imaging is also becoming an important task in regions
where imaging modalities are scarce and noninvasive,
inexpensive tests are needed [46]. Thus, our study
representing preimaging cohorts shows that LRG1, similar
to 4Kscore, can potentially be used to prioritise whom to
offer mpMR imaging. It would be of interest to perform
head-to-head comparisons with noninvasive tests aiming to
reduce overdiagnosis of clinically insignificant PCa. On the
contrary, the long span of the collection period is also a
strength because it shows that LRG1 is a prognostic marker
within multiple treatment regiments. Although we find
LRG1 adding significant information on disease aggres-
siveness at the diagnosis of high-risk and metastatic
disease, there has been vast improvements in both novel
treatment strategies, optimal treatment matching and
assessing treatment effects for these patients, which
provide better outcomes overall. Thus, prospective studies
that allow for parallel investigation of patient assessments
and management with or without LRG1 values, including
head-to-head comparisons with novel noninvasive tests
and imaging, will be essential to gather sound evidence and
facilitate clinical implementation. Moreover, although great
resources have been spent to develop new tests for
improving patient management in PCa, to date, very limited
data are available on cost and benefits, and clinical
adoption. However, so far, we have found LRG1 as a
prognostic biomarker irrespective of the study design,
participant selection, or study date.
E U R O P E A N U R O L O G Y O P E N S C I E N C E 2 1 ( 2 0 2 0 ) 5 1 – 6 0 595. Conclusions
We have found that elevated blood levels of LRG1 are
unfavourable in patients with newly diagnosed high-risk or
metastatic PCa. Thus, our study has established LRG1 as a
convincing candidate for inclusion in studies aiming to
improve PCa management.
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